Hereditary combined deficiency of the vitamin K-dependent clotting factors
<p>Abstract</p> <p>Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-07-01
|
Series: | Orphanet Journal of Rare Diseases |
Online Access: | http://www.ojrd.com/content/5/1/21 |
id |
doaj-eaf329b6c4f0400db0a65f490ab4f878 |
---|---|
record_format |
Article |
spelling |
doaj-eaf329b6c4f0400db0a65f490ab4f8782020-11-25T00:32:14ZengBMCOrphanet Journal of Rare Diseases1750-11722010-07-01512110.1186/1750-1172-5-21Hereditary combined deficiency of the vitamin K-dependent clotting factorsMariani GuglielmoNapolitano MariasantaLapecorella Mario<p>Abstract</p> <p>Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in the genes of either <it>gamma-glutamyl carboxylase </it>or <it>vitamin K2,3-epoxide reductase complex</it>. These two proteins are necessary for gamma-carboxylation, a post-synthetic modification that allows coagulation proteins to display their proper function. The developmental and skeletal anomalies seen in VKCFD are the result of defective gamma-carboxylation of a number of non-haemostatic proteins. Diagnostic differentiation from other conditions, both congenital and acquired, is mandatory and genotype analysis is needed to confirm the defect. Vitamin K administration is the mainstay of therapy in VKCFD, with plasma supplementation during surgery or severe bleeding episodes. In addition, prothrombin complex concentrates and combination therapy with recombinant activated FVII and vitamin K supplementation may constitute alternative treatment options. The overall prognosis is good and with the availability of several effective therapeutic options, VKCFD has only a small impact on the quality of life of affected patients.</p> http://www.ojrd.com/content/5/1/21 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mariani Guglielmo Napolitano Mariasanta Lapecorella Mario |
spellingShingle |
Mariani Guglielmo Napolitano Mariasanta Lapecorella Mario Hereditary combined deficiency of the vitamin K-dependent clotting factors Orphanet Journal of Rare Diseases |
author_facet |
Mariani Guglielmo Napolitano Mariasanta Lapecorella Mario |
author_sort |
Mariani Guglielmo |
title |
Hereditary combined deficiency of the vitamin K-dependent clotting factors |
title_short |
Hereditary combined deficiency of the vitamin K-dependent clotting factors |
title_full |
Hereditary combined deficiency of the vitamin K-dependent clotting factors |
title_fullStr |
Hereditary combined deficiency of the vitamin K-dependent clotting factors |
title_full_unstemmed |
Hereditary combined deficiency of the vitamin K-dependent clotting factors |
title_sort |
hereditary combined deficiency of the vitamin k-dependent clotting factors |
publisher |
BMC |
series |
Orphanet Journal of Rare Diseases |
issn |
1750-1172 |
publishDate |
2010-07-01 |
description |
<p>Abstract</p> <p>Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in the genes of either <it>gamma-glutamyl carboxylase </it>or <it>vitamin K2,3-epoxide reductase complex</it>. These two proteins are necessary for gamma-carboxylation, a post-synthetic modification that allows coagulation proteins to display their proper function. The developmental and skeletal anomalies seen in VKCFD are the result of defective gamma-carboxylation of a number of non-haemostatic proteins. Diagnostic differentiation from other conditions, both congenital and acquired, is mandatory and genotype analysis is needed to confirm the defect. Vitamin K administration is the mainstay of therapy in VKCFD, with plasma supplementation during surgery or severe bleeding episodes. In addition, prothrombin complex concentrates and combination therapy with recombinant activated FVII and vitamin K supplementation may constitute alternative treatment options. The overall prognosis is good and with the availability of several effective therapeutic options, VKCFD has only a small impact on the quality of life of affected patients.</p> |
url |
http://www.ojrd.com/content/5/1/21 |
work_keys_str_mv |
AT marianiguglielmo hereditarycombineddeficiencyofthevitaminkdependentclottingfactors AT napolitanomariasanta hereditarycombineddeficiencyofthevitaminkdependentclottingfactors AT lapecorellamario hereditarycombineddeficiencyofthevitaminkdependentclottingfactors |
_version_ |
1725320176615817216 |